By Katherine Hamilton
ScPharmaceuticals shares fell Wednesday morning after it disclosed it might have to delay submitting a new product to the Food and Drug Administration.
Shares were down 8% to $3.25 in recent trading. The stock is down about 61.3% this year.
One lot of the company's SCP-111 combination product showed varying results in shelf-life testing, which is the amount of time a product can maintain an acceptable level of quality, the company said in a Wednesday filing.
SCP-111 is designed to treat fluid overload and retention.
The variation could delay when the company submits a supplemental new drug application for the product with the FDA.
ScPharmaceuticals was planning to submit the product for approval in January, but may delay until later in 2025, the company said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 11, 2024 10:24 ET (15:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.